Syndax Pharmaceuticals Inc.

211 articles with Syndax Pharmaceuticals Inc.

• Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

  12/11/2021

  Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease despite two or more prior lines of therapy.

• Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update

  11/15/2021

   Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2021. In addition, the Company provided a clinical and business update.

• Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021

  11/8/2021

  Syndax Pharmaceuticals, Inc. announced today that it will release its third quarter 2021 financial results on Monday, November 15, after the close of the U.S. financial markets.

• Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting

  11/4/2021

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), today announced that updated data from both of its ongoing SNDX-5613 and axatilimab programs will be featured during oral sessions at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11-14, 2021.

• Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

  9/27/2021

  Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody.

• Syndax Appoints Martin H. Huber, M.D., to its Board of Directors

  9/15/2021

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the expansion of its Board of Directors to nine members with the appointment of Martin H. Huber, M.D.

• Syndax Announces Participation at Three Upcoming Investor Conferences in September 2021

  9/2/2021

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in three upcoming virtual investor conferences.

• Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update

  8/9/2021

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2021. In addition, the Company provided a clinical and business update.

• Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

  8/2/2021

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its second quarter 2021 financial results on Monday, August 9, after the close of the U.S. financial markets.

• SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias

  6/28/2021

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged or nucleophosmin mutation.

• 

  AskBio, Syndax and Catalyst All on the Fast Track

  6/28/2021

  The U.S. FDA granted Fast Track Designation to three biopharma companies for the treatment of LGMD, episodic bleeding and leukemia.

• Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

  6/3/2021

   Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021

• Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit

  5/13/2021

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021

• Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update

  5/11/2021

  Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23%

• Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

  5/4/2021

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.

• Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias

  4/20/2021

  48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status

• 

  Syndax Posts Positive Phase I Data in Genetically-Defined Acute Leukemias

  4/20/2021

  Syndax Pharmaceuticals announced its treatment for mixed-lineage leukemia demonstrated robust clinical activity in a Phase I/II study.

• Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias

  4/15/2021

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20,

• Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

  4/8/2021

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab

• Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease

  3/31/2021

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab,